Otani A, Takagi H, Suzuma K, Honda Y
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Japan.
Circ Res. 1998 Mar 23;82(5):619-28. doi: 10.1161/01.res.82.5.619.
Angiotensin II (Ang II) plays a role in the development of many vascular diseases. In the present study, we have investigated the effect of Ang II on vascular endothelial growth factor (VEGF) receptor expression and VEGF-induced angiogenic activity in bovine retinal microcapillary endothelial cells (BRECs). Ang II induced a significant increase of kinase domain-containing receptor/total liver kinase (KDR/Flk-1) mRNA in a time- and dose-dependent manner, with a maximal 4.3+/-0.8-fold increase after a 4-hour stimulation. Ang II increased the rate of KDR gene transcription by 5.4-fold, whereas the half-life of KDR mRNA was not increased significantly. The increase depended partially on new protein synthesis. The Ang II-induced KDR mRNA increase was inhibited by either [Sar1,Ile8]angiotensin or angiotensin type 1 receptor antagonists but was not significantly altered by angiotensin type 2 receptor antagonists. The PKC inhibitor reduced Ang II-induced KDR mRNA expression by 70+/-15%. The tyrosine kinase inhibitor reduced the Ang II- and phorbol 12-myristate 13-acetate-induced KDR mRNA increases by 35+/-8% and 44+/-26%, respectively. Ang II increased by 3.1-fold the 35S-labeled KDR/Flk-1 immunoprecipitated by a specific antibody to KDR/Flk-1. Scatchard analysis demonstrated that Ang II induced a significant increase of binding sites without changing binding affinity. Ang II enhanced VEGF-induced cell growth and tube formation. Ang II itself had no effect on cell growth, tube formation, or mRNA levels of VEGF and tms-like tyrosine kinase (Flt-1) in BRECs. These findings suggest that Ang II might potentiate VEGF-induced angiogenic activity through an increase of the VEGF receptor KDR/Flk-1.
血管紧张素II(Ang II)在多种血管疾病的发展过程中发挥作用。在本研究中,我们调查了Ang II对牛视网膜微血管内皮细胞(BRECs)中血管内皮生长因子(VEGF)受体表达及VEGF诱导的血管生成活性的影响。Ang II以时间和剂量依赖的方式显著增加含激酶结构域受体/总肝激酶(KDR/Flk-1)mRNA的表达,在4小时刺激后最大增加4.3±0.8倍。Ang II使KDR基因转录速率增加5.4倍,而KDR mRNA的半衰期没有显著增加。这种增加部分依赖于新蛋白质的合成。[Sar1,Ile8]血管紧张素或1型血管紧张素受体拮抗剂可抑制Ang II诱导的KDR mRNA增加,但2型血管紧张素受体拮抗剂对此没有显著影响。蛋白激酶C(PKC)抑制剂使Ang II诱导的KDR mRNA表达降低70±15%。酪氨酸激酶抑制剂使Ang II和佛波醇12-肉豆蔻酸酯13-乙酸酯诱导的KDR mRNA增加分别降低35±8%和44±26%。Ang II使用KDR/Flk-1特异性抗体免疫沉淀的35S标记的KDR/Flk-1增加3.1倍。Scatchard分析表明,Ang II诱导结合位点显著增加,而不改变结合亲和力。Ang II增强VEGF诱导的细胞生长和管形成。Ang II本身对BRECs中的细胞生长、管形成或VEGF及类tms酪氨酸激酶(Flt-1)的mRNA水平没有影响。这些发现表明,Ang II可能通过增加VEGF受体KDR/Flk-1来增强VEGF诱导的血管生成活性。